|
1
|
Bashour FN, Teran JC and Mullen KD:
Prevalence of peripheral blood cytopenias (hypersplenism) in
patients with nonalcoholic chronic liver disease. Am J
Gastroenterol. 95:2936–2939. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peck-Radosavljevic M: Thrombocytopenia in
liver disease. Can J Gastroenterol. 14(Suppl D): 60D–66D.
2000.PubMed/NCBI
|
|
3
|
Giannini EG: Review article:
Thrombocytopenia in chronic liver disease and pharmacologic
treatment options. Aliment Pharmacol Ther. 23:1055–1065. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moreno A, Bárcena R, Blázquez J, Quereda
C, Gil-Grande L, Sánchez J, Moreno L, Perez-Elías MJ, Antela A,
Moreno J, et al: Partial splenic embolization for the treatment of
hypersplenism in cirrhotic HIV/HCV patients prior to pegylated
interferon and ribavirin. Antivir Ther. 9:1027–1030.
2004.PubMed/NCBI
|
|
5
|
de Oliveira AC: Treatment options in the
management of thrombocytopenia in patients infected with HCV. Braz
J Infect Dis. 11(Suppl 1): 71–72. 2007. View Article : Google Scholar
|
|
6
|
Fried MW, Shiffman ML, Reddy KL, Smith C,
Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G,
Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic
hepatitis C virus infection. N Engl J Med. 347:975–982. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Manns MP, McHutchison JG, Gordon SC,
Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M
and Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with
interferon alfa-2b plus ribavirin for initial treatment of chronic
hepatitis C: A randomised trial. Lancet. 358:958–965. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bussel JB and Marks KM: How effective is
eltrombopag for the treatment of thrombocytopenia in patients with
HCV infection? Nat Clin Pract Gastroenterol Hepatol. 5:424–425.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cholongitas E, Papatheodoridis GV, Vangeli
M, Terreni N, Patch D and Burroughs AK: Systematic review: The
model for end-stage liver disease - should it replace Child-Pugh's
classification for assessing prognosis in cirrhosis? Aliment
Pharmacol Ther. 22:1079–1089. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lackner C, Struber G, Bankuti C, Bauer B
and Stauber RE: Noninvasive diagnosis of cirrhosis in chronic
hepatitis C based on standard laboratory tests. Hepatology.
43:378–379. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McHutchison JG, Dusheiko G, Shiffman ML,
Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC,
Campbell FM, Theodore D, et al: TPL102357 Study Group: Eltrombopag
for thrombocytopenia in patients with cirrhosis associated with
hepatitis C. N Engl J Med. 357:2227–2236. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
O'Brien PC and Fleming TR: A multiple
testing procedure for clinical trials. Biometrics. 35:549–556.
1979. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Manns M, Wedemeyer H and Cornberg M:
Treating viral hepatitis C: Efficacy, side effects and
complications. Gut. 55:1350–1359. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gutfreund K and Bain V: Chronic viral
hepatitis C: Management update. CMAJ. 162:827–833. 2000.PubMed/NCBI
|
|
15
|
Ikezawa K, Naito M, Yumiba T, Iwahashi K,
Onishi Y, Kita H, Nishio A, Kanno T, Matsuura T, Ono A, et al:
Splenectomy and antiviral treatment for thrombocytopenic patients
with chronic hepatitis C virus infection. J Viral Hepat.
17:488–492. 2010.PubMed/NCBI
|
|
16
|
Neunert C, Lim W, Crowther M, Cohen A,
Solberg L Jr and Crowther MA: American Society of Hematology: The
American society of hematology 2011 evidence-based practice
guideline for immune thrombocytopenia. Blood. 117:4190–4207. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Provan D, Stasi R, Newland AC, Blanchette
VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB,
Godeau B, et al: International consensus report on the
investigation and management of primary immune thrombocytopenia.
Blood. 115:168–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bussel JB, Buchanan GR, Nugent DJ, Gnarra
DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K and Jun S: A
randomized, double-blind study of romiplostim to determine its
safety and efficacy in children with immune thrombocytopenia.
Blood. 118:28–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tiede MP, Ahn ER, Jy W, Scagnelli T, Bidot
CJ, Horstman LL, Jimenez JJ and Ahn YS: Life-threatening
hypercoagulable state following splenectomy in ITP: Successful
management with aggressive antithrombotic therapy and danazol. Clin
Appl Thromb Hemost. 11:347–352. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Crary S and Buchanan G: Vascular
complications after splenectomy for hematologic disorders. Blood.
114:2861–2868. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Blanchette V and Bolton-Maggs P: Childhood
immune thrombocytopenic purpura: Diagnosis and management. Hematol
Oncol Clin North Am. 24:249–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deutsch VR and Tomer A: Megakaryocyte
development and platelet production. Br J Haemotol. 134:453–466.
2006. View Article : Google Scholar
|
|
23
|
Temel T, Cansu DU, Temel HE and Ozakyol
AH: Serum thrombopoietin levels and its relationship with
thrombocytopenia in patients with cirrhosis. Hepat Mon.
14:e185562014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang ES, Lyons RM, Larson RA, Gandhi S,
Liu D, Matei C, Scott B, Hu K and Yang AS: A randomized,
double-blind, placebo-controlled phase 2 study evaluating the
efficacy and safety of romiplostim treatment of patients with low
or intermediate-1 risk myelodysplastic syndrome receiving
lenalidomide. J Hematol Oncol. 5:712012. View Article : Google Scholar : PubMed/NCBI
|
